2. Search Result
Search Result
Results for "

δ-aminolevulinic

" in MedChemExpress (MCE) Product Catalog:

27

Inhibitors & Agonists

16

Peptides

5

Natural
Products

6

Isotope-Labeled Compounds

2

Oligonucleotides

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-N0305
    5-Aminolevulinic acid hydrochloride
    Maximum Cited Publications
    20 Publications Verification

    5-ALA hydrochloride; δ-aminolevulinic acid hydrochloride; 5-Amino-4-oxopentanoic acid hydrochloride

    		 Reactive Oxygen Species (ROS) Neurological Disease Metabolic Disease Inflammation/Immunology Cancer
    5-Aminolevulinic acid (5-ALA; δ-Aminolevulinic acid; 5-Amino-4-oxopentanoic acid) hydrochloride is an orally active heme precursor. 5-Aminolevulinic acid hydrochloride promotes aerobic energy metabolism and increases ATP levels by enhancing the activity of cytochrome c oxidase. 5-Aminolevulinic acid hydrochloride enhances LPS-induced proinflammatory cytokine production and gene activation, and restores the phagocytic activity and ROS generation capacity of neutrophils. 5-Aminolevulinic acid hydrochloride selectively accumulates protoporphyrin IX in tumor cells; as a photosensitizer and radiosensitizer, it induces ROS burst upon light or X-ray irradiation to inhibit tumor growth. 5-Aminolevulinic acid hydrochloride can be applied to the research of septic shock, melanoma, and cancer radiotherapy .
    5-Aminolevulinic acid hydrochloride
  • HY-W000450
    5-Aminolevulinic acid
    Maximum Cited Publications
    20 Publications Verification

    5-ALA; δ-aminolevulinic acid; 5-Amino-4-oxopentanoic acid

    		 Reactive Oxygen Species (ROS) Cardiovascular Disease Cancer
    5-Aminolevulinic acid (5-ALA; δ-Aminolevulinic acid; 5-Amino-4-oxopentanoic acid) is an orally active heme precursor. 5-Aminolevulinic acid promotes aerobic energy metabolism and increases ATP levels by enhancing the activity of cytochrome c oxidase. 5-Aminolevulinic acid enhances LPS-induced proinflammatory cytokine production and gene activation, and restores the phagocytic activity and ROS generation capacity of neutrophils. 5-Aminolevulinic acid selectively accumulates protoporphyrin IX in tumor cells; as a photosensitizer and radiosensitizer, it induces ROS burst upon light or X-ray irradiation to inhibit tumor growth. 5-Aminolevulinic acid can be applied to the research of septic shock, melanoma, and cancer radiotherapy .
    5-Aminolevulinic acid
  • HY-132610A
    Givosiran sodium
    1 Publications Verification

    ALN-AS1 sodium

    		 Small Interfering RNA (siRNA) Metabolic Disease
    Givosiran (ALN-AS1) sodium is a small interfering RNA that targets hepatic aminolevulinate synthase 1 (ALAS1) messenger RNA. Givosiran sodium downregulates ALAS1 mRNA and prevents accumulation of neurotoxic δ-aminolevulinic acid (ALA) and porphobilinogen (PBG) levels. Givosiran sodium demonstrates potent inhibitory activity against ALAS1 in mouse, rat, and cynomolgus monkey models. Givosiran sodium can be used for the research of acute hepatic porphyria (AHP) .
    Givosiran sodium
  • HY-132610
    Givosiran
    1 Publications Verification

    ALN-AS1

    		 Small Interfering RNA (siRNA) Metabolic Disease
    Givosiran (ALN-AS1) is a small interfering RNA that targets hepatic aminolevulinate synthase 1 (ALAS1) messenger RNA. Givosiran downregulates ALAS1 mRNA and prevents accumulation of neurotoxic δ-aminolevulinic acid (ALA) and porphobilinogen (PBG) levels. Givosiran demonstrates potent inhibitory activity against ALAS1 in mouse, rat, and cynomolgus monkey models. Givosiran can be used for the research of acute hepatic porphyria (AHP) .
    Givosiran
  • HY-P4070
    Insulin icodec

    		Insulin Receptor Metabolic Disease
    Insulin icodec is an Insulin (HY-P0035) analog that strongly but reversibly binds to albumin. Insulin icodec has long plasma half-life. Insulin icodec modulates insulin receptor activity, controls blood glucose levels, reduces HbA1c levels, and binds reversibly to human serum albumin. Insulin icodec can be used for the research of type 2 diabetes mellitus .
    Insulin icodec
  • HY-P5362
    NODAGA-LM3

    		Radionuclide-Drug Conjugates (RDCs) Somatostatin Receptor Neurological Disease Cancer
    NODAGA-LM3 is a ligand that can cross the blood-brain barrier and targets somatostatin receptor SSTR2 with high affinity (IC50 = 1.3 nM). NODAGA-LM3 does not trigger the internalization of SSTR2 and can inhibit agonist-induced internalization processes. NODAGA-LM3 shows low uptake in normal tissues such as the liver and spleen, but high uptake in the lungs and blood pool. 68Ga-labeled NODAGA-LM3 can serve as a PET imaging agent for well-differentiated neuroendocrine tumors, and is applied in studies related to small cell lung cancer and well-differentiated neuroendocrine tumors .
    NODAGA-LM3
  • HY-P2336A
    CCZ01048 TFA
    3 Publications Verification

    		 Melanocortin Receptor Cancer
    CCZ01048 TFA, a α-MSH analogue, exhibits high binding affinity to melanocortin 1 receptor (MC1R) with a Ki of 0.31 nM. CCZ01048 TFA shows rapid internalization into B16F10 melanoma cells and high in vivo stability. CCZ01048 TFA is a promising candidate for PET imaging of malignant melanoma .
    CCZ01048 TFA
  • HY-N0305R
    5-Aminolevulinic acid hydrochloride (Standard)
    10+ Cited Publications

    5-ALA hydrochloride (Standard); δ-aminolevulinic acid hydrochloride (Standard); 5-Amino-4-oxopentanoic acid hydrochloride (Standard)

    		 Autophagy Endogenous Metabolite Apoptosis Mitophagy Reference Standards Metabolic Disease Cancer
    5-Aminolevulinic acid (hydrochloride) (Standard) is the analytical standard of 5-Aminolevulinic acid (hydrochloride). This product is intended for research and analytical applications. 0
    5-Aminolevulinic acid hydrochloride (Standard)
  • HY-148285
    Succinyl CoA

    Succinyl-coenzyme A; S-(Hydrogen succinyl)coenzyme A

    		 Endogenous Metabolite Metabolic Disease
    Succinyl CoA (Succinyl-coenzyme A) is a pivotal intermediate metabolite in the tricarboxylic acid cycle and a key coenzyme A metabolite. Succinyl CoA is biosynthesized from α-ketoglutarate or propionyl-CoA. Succinyl CoA acts as a critical precursor and substrate for heme biosynthesis and gluconeogenesis. Succinyl CoA insufficiency caused by cobalamin deficiency is directly linked to growth retardation, impaired heme synthesis, tissue glycine accumulation and neurological abnormalities. Succinyl CoA can be used in research on metabolic, neurological, and hematological abnormalities (such as porphyria) caused by nutritional vitamin B12 deficiency (leading to a lack of Succinyl-Coenzyme A synthesis) .
    Succinyl CoA
  • HY-W749251
    5-Aminolevulinic acid-13C2,15N hydrochloride

    5-ALA-13C2,15N hydrochloride; δ-aminolevulinic acid-13C2,15N hydrochloride; 5-Amino-4-oxopentanoic acid-13C2,15N hydrochloride

    		 Endogenous Metabolite Isotope-Labeled Compounds Others
    5-Aminolevulinic acid- 13C2, 15N (5-ALA- 13C2, 15N; δ-Aminolevulinic acid- 13C2, 15N) is 13C- and 15N-labeled 5-Aminolevulinic acid (HY-W000450) .
    5-Aminolevulinic acid-13C2,15N hydrochloride
  • HY-N0305S
    5-Aminolevulinic acid-15N hydrochloride

    5-ALA-15N hydrochloride; δ-aminolevulinic acid-15N hydrochloride; 5-Amino-4-oxopentanoic acid-15N hydrochloride

    		 Isotope-Labeled Compounds Autophagy Mitophagy Endogenous Metabolite Apoptosis Metabolic Disease Cancer
    5-Aminolevulinic acid- 15N (hydrochloride) is the 15N-labeled 5-Aminolevulinic acid (hydrochloride). 5-Aminolevulinic acid hydrochloride (5-ALA hydrochloride) is an intermediate in heme biosynthesis in the body and the universal precursor of tetrapyrroles.
    5-Aminolevulinic acid-15N hydrochloride
  • HY-P10341
    ZP3022

    		GCGR Metabolic Disease
    ZP3022 is a dual agonist of glucagon-like peptide-1 (GLP-1) and gastrin that has the ability to sustainably improve glycemic control. Additionally, ZP3022 can effectively increase β-cell mass, promote β-cell proliferation, and enhance the function of pancreatic islets. ZP3022 can be used in anti-diabetic research .
    ZP3022
  • HY-N0305S1
    5-Aminolevulinic acid-d2 hydrochloride

    5-ALA-d2 hydrochloride; δ-aminolevulinic acid-d2 hydrochloride; 5-Amino-4-oxopentanoic acid-d2 hydrochloride

    		 Isotope-Labeled Compounds Autophagy Mitophagy Endogenous Metabolite Apoptosis Metabolic Disease Cancer
    5-Aminolevulinic acid-d2 (hydrochloride) is deuterium labeled 5-Aminolevulinic acid (hydrochloride).
    5-Aminolevulinic acid-d2 hydrochloride
  • HY-N0305S3
    5-Aminolevulinic acid-13C-1 hydrochloride

    5-ALA-13C-1 hydrochloride; δ-aminolevulinic acid-13C-1 hydrochloride; 5-Amino-4-oxopentanoic acid-13C-1 hydrochloride

    		 Apoptosis Autophagy Mitophagy Endogenous Metabolite Metabolic Disease
    5-Aminolevulinic acid- 13C-1 (5-ALA- 13C-1) hydrochloride is the 13C labeled 5-Aminolevulinic acid hydrochloride . 5-Aminolevulinic acid hydrochloride (5-ALA hydrochloride) is an intermediate in heme biosynthesis in the body and the universal precursor of tetrapyrroles .
    5-Aminolevulinic acid-13C-1 hydrochloride
  • HY-W000450S
    5-Aminolevulinic acid-13C

    5-ALA-13C; δ-aminolevulinic acid-13C; 5-Amino-4-oxopentanoic acid-13C

    		 Isotope-Labeled Compounds Endogenous Metabolite Cardiovascular Disease
    5-Aminolevulinic acid- 13C is the 13C-labeled 5-Aminolevulinic acid. 5-Aminolevulinic acid (5-ALA) is a non-protein amino acid that plays a rate-limiting role in heme biosynthesis.
    5-Aminolevulinic acid-13C
  • HY-N0305S2
    5-Aminolevulinic acid-13C hydrochloride

    5-ALA-13C hydrochloride; δ-aminolevulinic acid-13C hydrochloride; 5-Amino-4-oxopentanoic acid-13C hydrochloride

    		 Apoptosis Autophagy Mitophagy Endogenous Metabolite Metabolic Disease
    5-Aminolevulinic acid- 13C (hydrochloride) is the 13C labeled 5-Aminolevulinic acid hydrochloride . 5-Aminolevulinic acid hydrochloride (5-ALA hydrochloride) is an intermediate in heme biosynthesis in the body and the universal precursor of tetrapyrroles .
    5-Aminolevulinic acid-13C hydrochloride
  • HY-P11004
    A3-APO

    		Bacterial Antibiotic Infection
    A3-APO is an antimicrobial peptide. A3-APO has a significant antimicrobial activity by a dual mode of action with both membrane disintegration and intracellular target inhibition. A3-APO can deactivate bacterial toxins and increase the expression of anti-inflammatory cytokines (such as IL-4 and IL-10), without antimicrobial resistance. A3-APO accelerates burn wounds healing in mice infection model of Acinetobacter baumannii and Staphylococcus aureus .
    A3-APO
  • HY-P10472
    Azaline B

    		GnRH Receptor Endocrinology
    Azaline B is an antagonist for gonadotropin-releasing hormone (GnRH) with IC50 of 1.37 nM, Azaline B can be used in research of sex hormone-related pathological states, ovulation induction and male contraception .
    Azaline B
  • HY-P4757
    N1-Glutathionyl-spermidine disulfide

    		Parasite Others
    N1-Glutathionyl-spermidine disulfide is a substrate of trypanothione reductase .
    N1-Glutathionyl-spermidine disulfide
  • HY-P11243
    EphA4 agonist compound 23

    		Ephrin Receptor Neurological Disease
    EphA4 agonist compound 23 is a novel EphA4 agonist peptide mimic. EphA4 agonist compound 23 exhibits high affinity, high selectivity, and significant receptor activation ability. EphA4 agonist compound 23 is commonly used in the study of neurodegenerative diseases .
    EphA4 agonist compound 23
  • HY-P2434
    AP102

    		Somatostatin Receptor Neurological Disease Metabolic Disease Cancer
    AP102 is a dual SSTR2/SSTR5-specific somatostatin analog (SSA). AP102 is a disulfide-bridged octapeptide SSA containing synthetic iodinated amino acids. AP102 binds with subnanomolar affinity to SSTR2 and SSTR5 (IC50: 0.63 and 0.65 nM, respectively). AP102 does not bind to SSTR1 or SSTR3. AP102 can be used for acromegaly and neuroendocrine tumors research .
    AP102
  • HY-P5362A
    NODAGA-LM3 TFA

    		Radionuclide-Drug Conjugates (RDCs) Somatostatin Receptor Cancer
    NODAGA-LM3 TFA is a ligand that can cross the blood-brain barrier and targets somatostatin receptor SSTR2 with high affinity (IC50 = 1.3 nM). NODAGA-LM3 TFA does not trigger the internalization of SSTR2 and can inhibit agonist-induced internalization processes. NODAGA-LM3 TFA shows low uptake in normal tissues such as the liver and spleen, but high uptake in the lungs and blood pool. 68Ga-labeled NODAGA-LM3 TFA can serve as a PET imaging agent for well-differentiated neuroendocrine tumors, and is applied in studies related to small cell lung cancer and well-differentiated neuroendocrine tumors .
    NODAGA-LM3 TFA
  • HY-105168
    TAK 044

    		Endothelin Receptor Cardiovascular Disease
    TAK 044 is an antagonist of Endothelin Receptor. TAK 044 strongly inhibits ET-induced deterioration in various animal models. TAK 044 can be used in study ET-related diseases such as acute myocardial infarction,acute renal failure, acute hepatic malfunction, and subarachnoid hemorrhage .
    TAK 044
  • HY-P2075
    EMD 55068

    		Renin Endocrinology
    EMD 55068 is a renin antagonist. EMD 55068 inhibits the uptake of taurocholate .
    EMD 55068
  • HY-P10876
    mcK6A1

    		Amyloid-β Neurological Disease
    mcK6A1 is an inhibitor for the aggregation of amyloid-β (Aβ), that selectively binds to the 16KLVFFA21 segment of Aβ42, forms an extended β-folded structure, and inhibits the formation of Aβ42 oligomers. mcK6A1 can be used in research of Alzheimer's disease and other amyloid-related diseases .
    mcK6A1
  • HY-P11488
    JR11-PEG3-DOTA-PSMA-03

    		Radionuclide-Drug Conjugates (RDCs) Somatostatin Receptor PSMA Cancer
    JR11-PEG3-DOTA-PSMA-03 (Compound 2) is an RDC-related compound containing the chelating agent DOTA (HY-W053583), the JR11 peptide (SSTR2 antagonist), and the PSMA ligand. JR11-PEG3-DOTA-PSMA-03 shows SSTR2-binding affinities and PSMA-binding affinities, with IC50 s of 94.0 nM, 81.8 nM, respectively. JR11-PEG3-DOTA-PSMA-03 can be radiolabeled with [ 68Ga]. [ 68Ga] radiolabeled JR11-PEG3-DOTA-PSMA-03 can be used in diagnostic studies of neuroendocrine differentiated prostate cancer .
    JR11-PEG3-DOTA-PSMA-03
  • HY-P11485
    JR11-PEG3-HBED-CC-PSMA-03

    		Radionuclide-Drug Conjugates (RDCs) Somatostatin Receptor PSMA Cancer
    JR11-PEG3-HBED-CC-PSMA-03 (Compound 1) is an RDC-related compound containing the chelating agent HBED-CC, the JR11 peptide (SSTR2 antagonist), and the PSMA ligand. JR11-PEG3-HBED-CC-PSMA-03 shows SSTR2-binding affinities and PSMA-binding affinities, with IC50 s of 59.2 nM, 57.0 nM, respectively. JR11-PEG3-HBED-CC-PSMA-03 can be radiolabeled with [ 68Ga]. [ 68Ga] radiolabeled JR11-PEG3-HBED-CC-PSMA-03 can be used in diagnostic studies of neuroendocrine differentiated prostate cancer .
    JR11-PEG3-HBED-CC-PSMA-03

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: